T-cell leukemia 1(TCL1) als ein Modulator der B-Zell Rezeptor Signalübertragung - Analyse eines neuen Mechanismus in der Pathogenese der chronisch lymphatischen Leukämie (CLL)

• Applicant: Dr. Marco Herling
• Subject Area: Hematology, Oncology
• Term: from 2006 to 2011
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 30163949

• Final Report Year: 2012

Final Report Abstract

No abstract available

Publications

• Skin involvement in T-cell prolymphocytic leukemia (T-PLL). J Am Acad Dermatol 2007 Sep;57(3):533-4
  Herling M, Valbuena JR, Jones D, Medeiros LJ
  
• High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood 2008 Jan 1;111(1):328-37
  Herling M, Patel KA, Teitell MA, Konopleva M, Ravandi F, Kobayashi R, Jones D
  
• High TCL1 levels are a marker of B-cell receptor pathway responsiveness and therapy resistance in chronic lymphocytic leukemia. Blood 2009 Nov 19;114(21):4675-86
  Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ, Jones D
  
• Mature T-cell malignancies: a diagnostic and therapeutic challenge. Magazine of European Medical Oncology 2009;2:134-41
  Hopfinger G and Herling M
  
• Pharmacologic interception in TCL1-associated pathways as a treatment rationale for CLL. Leuk Lymphoma 2010 Aug; 51(8): 1375-78
  Popal W, Boucas J, Peer-Zada AA, Herling M
  
• Synthesis and selective anti-cancer activity of novel organotellurium based redox catalysts. J Med Chem 2010, Sep; 19: 6954-63
  Doering M, Ba LA, Lilienthal N, Nicco C, Scherer C, Abbas M, Peer-Zada AA, Coriat R, Burkholz T, Wessjohann L, Diederich M, Batteux F, Herling M, Jacob C
  
• Targeting the disturbed redox equilibrium in chronic lymphocytic leukaemia by novel ROS- catalytic ‘sensor/effector’ compounds. Leuk Lymphoma 2011 Jul;52(7):1407-11
  Lilienthal N, Prinz C, Peer-Zada AA., Doering M, Ba L.A., Hallek M, Jacob C, Herling M